MedTrace Logo

Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) </= 60y. After First CR

NCT01246752 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 143

Last updated 2021-10-29

No results posted yet for this study

Summary

Hematopoietic stem cell transplantation in patients with newly diagnosed AML ≤60 years of age in intermediate risk, after first complete response in comparison to standard consolidation chemotherapy

Conditions

  • Leukemia, Myeloid, Acute

Interventions

BIOLOGICAL

Human Stem Cell Transplantation

Human allogenic stem cells

DRUG

Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)

Consolidation chemotherapy, recommended regimen: HiDAC = 3 x 2g/sqm BID on days 1,3,5

Sponsors & Collaborators

  • German Research Foundation

    collaborator OTHER

  • University Hospital Carl Gustav Carus

    lead OTHER

Principal Investigators

  • Martin Bornhaeuser, Prof. (MD) · Universitätsklinikum Dresden, Medizinische Klinik und Poliklinik I, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-10
Primary Completion
2020-04-30
Completion
2020-04-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01246752 on ClinicalTrials.gov